Orthocell's September Quarter Revenue Meets Fiscal 2026 Expectations, Euroz Hartleys Says

MT Newswires Live

10/03

Orthocell's (ASX:OCC) record revenue of AU$3 million for the September quarter, up 9.1% quarter over quarter, is consistent with Euroz Hartleys' fiscal 2026 revenue estimate of AU$14.4 million, according to a Thursday note from the investment advisory firm.

The first-quarter growth was due to higher sales of Remplir, the company's nerve repair product, in Australia and Singapore, Euroz Hartleys said.

Though Remplir did not have a material revenue contribution from the US market, Euroz Hartleys noted that the company expects US sales to start ramping up from the December quarter.

"The US rollout of Remplir remains central to our investment thesis," the investment advisory firm added.

Euroz Hartleys maintained Orthocell's hold rating and raised its price target to AU$1.36 from AU$1.30.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2572631522"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572631522\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572631522?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-03 08:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572631522","market":"us","top_or_hot":-1,"title":"Orthocell's September Quarter Revenue Meets Fiscal 2026 Expectations, Euroz Hartleys Says","media":"MT Newswires Live","content":"<html><body><p> Orthocell's (ASX:OCC) record revenue of AU$3 million for the September quarter, up 9.1% quarter over quarter, is consistent with <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys' fiscal 2026 revenue estimate of AU$14.4 million, according to a Thursday note from the investment advisory firm.</p><p>The first-quarter growth was due to higher sales of Remplir, the company's nerve repair product, in Australia and Singapore, Euroz Hartleys said.</p><p>Though Remplir did not have a material revenue contribution from the US market, Euroz Hartleys noted that the company expects US sales to start ramping up from the December quarter.</p><p>\"The US rollout of Remplir remains central to our investment thesis,\" the investment advisory firm added.</p><p>Euroz Hartleys maintained Orthocell's hold rating and raised its price target to AU$1.36 from AU$1.30.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orthocell's September Quarter Revenue Meets Fiscal 2026 Expectations, Euroz Hartleys Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrthocell's September Quarter Revenue Meets Fiscal 2026 Expectations, Euroz Hartleys Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-03 08:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Orthocell's (ASX:OCC) record revenue of AU$3 million for the September quarter, up 9.1% quarter over quarter, is consistent with <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys' fiscal 2026 revenue estimate of AU$14.4 million, according to a Thursday note from the investment advisory firm.</p><p>The first-quarter growth was due to higher sales of Remplir, the company's nerve repair product, in Australia and Singapore, Euroz Hartleys said.</p><p>Though Remplir did not have a material revenue contribution from the US market, Euroz Hartleys noted that the company expects US sales to start ramping up from the December quarter.</p><p>\"The US rollout of Remplir remains central to our investment thesis,\" the investment advisory firm added.</p><p>Euroz Hartleys maintained Orthocell's hold rating and raised its price target to AU$1.36 from AU$1.30.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2572631522","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572631522","pubTimestamp":1759451674,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Orthocell's  record revenue of AU$3 million for the September quarter, up 9.1% quarter over quarter, is consistent with Euroz Hartleys' fiscal 2026 revenue estimate of AU$14.4 million, according to a Thursday note from the investment advisory firm.The first-quarter growth was due to higher sales of Remplir, the company's nerve repair product, in Australia and Singapore, Euroz Hartleys said.Though Remplir did not have a material revenue contribution from the US market, Euroz Hartleys noted that the company expects US sales to start ramping up from the December quarter.\"The US rollout of Remplir remains central to our investment thesis,\" the investment advisory firm added.Euroz Hartleys maintained Orthocell's hold rating and raised its price target to AU$1.36 from AU$1.30.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","OCC.AU":"ORTHOCELL LTD","BK7508":"医药生物股"},"translate_title":"Euroz Hartleys表示，Orthocell 9月份季度收入符合2026财年预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCC.AU":1},"content_text":"Orthocell's (ASX:OCC) record revenue of AU$3 million for the September quarter, up 9.1% quarter over quarter, is consistent with Euroz Hartleys' fiscal 2026 revenue estimate of AU$14.4 million, according to a Thursday note from the investment advisory firm.The first-quarter growth was due to higher sales of Remplir, the company's nerve repair product, in Australia and Singapore, Euroz Hartleys said.Though Remplir did not have a material revenue contribution from the US market, Euroz Hartleys noted that the company expects US sales to start ramping up from the December quarter.\"The US rollout of Remplir remains central to our investment thesis,\" the investment advisory firm added.Euroz Hartleys maintained Orthocell's hold rating and raised its price target to AU$1.36 from AU$1.30.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}